Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease

Background: Azathioprine and mercaptopurine (MP) are effective in treating patients with inflammatory bowel disease (IBD). Immunosuppressive effects of thiopurines involve T-cell apoptosis after inhibition of GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1). This study aimed to assess whether expression and activity of Rac1 or phosphorylated ezrin-radixin-moesin (pERM) in patients with IBD could provide a useful biomarker for the pharmacodynamic thiopurine effect and might be related to clinical effectiveness. Methods: This was a 2-stage study: stage 1 concerned a cross-sectional cohort of patients with IBD clinically in remission and treated with (n = 10) or without stable weight-based thiopurine therapy (n = 11) and healthy controls (n = 6); stage 2 concerned a prospective study regarding IBD patients with clinically active disease who initiated MP therapy (n = 11) compared with healthy controls (n = 11). Expression and activity of Rac1 and ERM and pERM were determined. Results: The median Rac1 expression was statistically significantly reduced by thiopurine maintenance therapy {0.54 [interquartile range (IQR) 0.47–0.88] versus 0.80 arbitrary units [IQR 0.64–1.46]} compared with patients without immunosuppressive therapy (P = 0.042), but not Rac1 activity and pERM. In responders to MP therapy (n = 6), both median active Rac1 [93 (IQR 81–151) to 76 ng Rac1/mg protein (IQR 62–98)] and Rac1 expression [16.2 (8.8–29.4) to 1.5 arbitrary units (0.9–5.3)] decreased (P = 0.028). In nonresponders (n = 3), Rac1 expression and activity increased. Conclusions: IBD patients treated with thiopurines had a lower expression of Rac1 compared with those not treated with thiopurine. Effective MP therapy led to decreasing concentrations of Rac1-GTP and Rac1 expression. Therefore, Rac1-GTP and expression of Rac1, but not phosphorylation of ERM, form potentially pharmacodynamic markers of therapeutic thiopurine effectiveness in patients with IBD.

[1]  K. Faber,et al.  Suppression of p21Rac Signaling and Increased Innate Immunity Mediate Remission in Crohn’s Disease , 2014, Science Translational Medicine.

[2]  R. Eliakim,et al.  Thiopurine Effectiveness in Patients with Crohn's Disease: A Study of Genetic and Clinical Predictive Factors , 2013, Inflammatory bowel diseases.

[3]  A. Paulussen,et al.  Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. , 2012, Journal of Crohn's & colitis.

[4]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[5]  F. Casellas,et al.  Thiopurine methyl‐transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine‐treated inflammatory bowel disease patients , 2011, Alimentary pharmacology & therapeutics.

[6]  J. Lo-Guidice,et al.  Evidence for a functional genetic polymorphism of the Rho-Gtpase Rac1: Implication in azathioprine response? , 2011 .

[7]  Judy H. Cho,et al.  Single nucleotide polymorphisms that increase expression of the guanosine triphosphatase RAC1 are associated with ulcerative colitis. , 2011, Gastroenterology.

[8]  R. Gearry,et al.  Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease , 2011, Inflammatory bowel diseases.

[9]  J. V. van Ginkel,et al.  Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts , 2010, Inflammatory bowel diseases.

[10]  N. D. de Boer,et al.  Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  G. Peters,et al.  On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance. , 2009, Current drug metabolism.

[12]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[13]  K. Sunagawa,et al.  Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptors , 2007, Journal of hypertension.

[14]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[15]  J. Lewis,et al.  Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. , 2006, Gastroenterology.

[16]  W. Best.  Predicting the Crohn's disease activity index from the harvey‐bradshaw index , 2006, Inflammatory bowel diseases.

[17]  M. Neurath,et al.  Azathioprine Suppresses Ezrin-Radixin-Moesin-Dependent T Cell-APC Conjugation through Inhibition of Vav Guanosine Exchange Activity on Rac Proteins , 2006, The Journal of Immunology.

[18]  A. Trautmann,et al.  ERM proteins regulate cytoskeleton relaxation promoting T cell–APC conjugation , 2004, Nature Immunology.

[19]  A. Takeshita,et al.  Rho/Rho-Kinase Pathway in the Brainstem Contributes to Hypertension Caused by Chronic Nitric Oxide Synthase Inhibition , 2004, Hypertension.

[20]  M. Neurath,et al.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. , 2003, The Journal of clinical investigation.

[21]  V. Armstrong,et al.  Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. , 2003, Clinical chemistry.

[22]  S. Targan,et al.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.

[23]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[24]  R. Boulieu,et al.  Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. , 1998, Clinical chemistry.

[25]  L. Lennard,et al.  High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. , 1992, Journal of chromatography.